Wall Street analysts expect ABIOMED, Inc. (NASDAQ:ABMD) to announce earnings per share of $0.87 for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for ABIOMED’s earnings. The highest EPS estimate is $1.25 and the lowest is $0.52. ABIOMED posted earnings per share of $1.03 during the same quarter last year, which would indicate a negative year-over-year growth rate of 15.5%. The business is scheduled to report its next quarterly earnings report on Thursday, October 29th.
On average, analysts expect that ABIOMED will report full-year earnings of $4.34 per share for the current year, with EPS estimates ranging from $3.85 to $5.34. For the next financial year, analysts anticipate that the company will report earnings of $5.03 per share, with EPS estimates ranging from $4.22 to $6.08. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for ABIOMED.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.38. ABIOMED had a net margin of 19.88% and a return on equity of 16.17%. The firm had revenue of $164.90 million during the quarter, compared to analysts’ expectations of $144.12 million. During the same period in the prior year, the company earned $1.00 EPS. The firm’s revenue was down 20.6% on a year-over-year basis.
A number of equities analysts have weighed in on ABMD shares. BidaskClub cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, August 25th. Morgan Stanley upped their price objective on shares of ABIOMED from $152.00 to $217.00 and gave the company an “underweight” rating in a research report on Friday, August 7th. OTR Global raised shares of ABIOMED to a “positive” rating in a research report on Monday, July 13th. Finally, SVB Leerink upped their price objective on shares of ABIOMED from $280.00 to $335.00 and gave the company a “market perform” rating in a research report on Friday, August 7th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $221.40.
NASDAQ:ABMD traded up $1.54 on Monday, reaching $261.99. The stock had a trading volume of 432,306 shares, compared to its average volume of 338,754. The company has a 50-day moving average of $286.58 and a 200 day moving average of $235.54. The stock has a market cap of $11.80 billion, a P/E ratio of 75.50, a price-to-earnings-growth ratio of 3.30 and a beta of 1.17. ABIOMED has a 12-month low of $119.01 and a 12-month high of $319.19.
In other news, Director Paul Thomas sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $303.41, for a total value of $606,820.00. Also, Director Dorothy E. Puhy sold 7,500 shares of the company’s stock in a transaction dated Wednesday, July 15th. The shares were sold at an average price of $275.00, for a total transaction of $2,062,500.00. Following the completion of the sale, the director now owns 7,652 shares in the company, valued at approximately $2,104,300. The disclosure for this sale can be found here. In the last 90 days, insiders sold 110,250 shares of company stock worth $33,815,313. Company insiders own 3.40% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Advisers LP raised its stake in ABIOMED by 57.4% during the second quarter. Two Sigma Advisers LP now owns 17,200 shares of the medical equipment provider’s stock worth $4,155,000 after acquiring an additional 6,269 shares during the period. Principal Financial Group Inc. raised its stake in ABIOMED by 7.5% during the second quarter. Principal Financial Group Inc. now owns 71,474 shares of the medical equipment provider’s stock worth $17,265,000 after acquiring an additional 4,971 shares during the period. PNC Financial Services Group Inc. raised its stake in ABIOMED by 1.2% during the second quarter. PNC Financial Services Group Inc. now owns 5,833 shares of the medical equipment provider’s stock worth $1,408,000 after acquiring an additional 67 shares during the period. Handelsbanken Fonder AB acquired a new stake in ABIOMED during the second quarter worth about $2,313,000. Finally, Nuveen Asset Management LLC raised its stake in ABIOMED by 11.6% during the second quarter. Nuveen Asset Management LLC now owns 209,822 shares of the medical equipment provider’s stock worth $50,684,000 after acquiring an additional 21,797 shares during the period. Hedge funds and other institutional investors own 94.94% of the company’s stock.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Recommended Story: What is the Current Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.